Tumor Microenvironment

• 

  Subject Areas on Research

  • 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers. 
  • A 3D Poly(ethylene glycol)-based Tumor Angiogenesis Model to Study the Influence of Vascular Cells on Lung Tumor Cell Behavior. 
  • A PK2/Bv8/PROK2 antagonist suppresses tumorigenic processes by inhibiting angiogenesis in glioma and blocking myeloid cell infiltration in pancreatic cancer. 
  • A multi-modal exploration of heterogeneous physico-chemical properties of DCIS breast microcalcifications. 
  • A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype. 
  • A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy. 
  • ACLY and ACC1 Regulate Hypoxia-Induced Apoptosis by Modulating ETV4 via α-ketoglutarate. 
  • AMPK Alpha-1 Intrinsically Regulates the Function and Differentiation of Tumor Myeloid-Derived Suppressor Cells. 
  • APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell-Mediated Antitumor Immune Responses. 
  • Acidic stress promotes a glioma stem cell phenotype. 
  • Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. 
  • Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy. 
  • Adipocyte mesenchymal transition contributes to mammary tumor progression. 
  • Adipose stem cell crosstalk with chemo-residual breast cancer cells: implications for tumor recurrence. 
  • Advanced Melanoma: Resistance Mechanisms to Current Therapies. 
  • Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. 
  • Aldolase B-Mediated Fructose Metabolism Drives Metabolic Reprogramming of Colon Cancer Liver Metastasis. 
  • Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients. 
  • An Engineered Tumor-on-a-Chip Device with Breast Cancer-Immune Cell Interactions for Assessing T-cell Recruitment. 
  • An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. 
  • Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. 
  • Anti-glioblastoma activity of monensin and its analogs in an organoid model of cancer. 
  • Atm deletion with dual recombinase technology preferentially radiosensitizes tumor endothelium. 
  • Automated Nuclear Segmentation in Head and Neck Squamous Cell Carcinoma Pathology Reveals Relationships between Cytometric Features and ESTIMATE Stromal and Immune Scores. 
  • Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment. 
  • BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. 
  • Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. 
  • Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer. 
  • Blocking Interleukin (IL)4- and IL13-Mediated Phosphorylation of STAT6 (Tyr641) Decreases M2 Polarization of Macrophages and Protects Against Macrophage-Mediated Radioresistance of Inflammatory Breast Cancer. 
  • Brachytherapy via a depot of biopolymer-bound 131I synergizes with nanoparticle paclitaxel in therapy-resistant pancreatic tumours. 
  • Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines. 
  • Brain Tumor Microenvironment and Host State: Implications for Immunotherapy. 
  • Brain immunology and immunotherapy in brain tumours. 
  • Breaking barriers for T cells by targeting the EPHA2/TGF-β/COX-2 axis in pancreatic cancer. 
  • Breast cancer brain metastases: evidence for neuronal-like adaptation in a 'breast-to-brain' transition? 
  • Broad immunophenotyping of the murine brain tumor microenvironment. 
  • CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade. 
  • CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation. 
  • CD200+ cytotoxic T lymphocytes in the tumor microenvironment are crucial for efficacious anti-PD-1/PD-L1 therapy. 
  • CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells. 
  • CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation. 
  • CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. 
  • CD90(+) stromal cells are the major source of IL-6, which supports cancer stem-like cells and inflammation in colorectal cancer. 
  • CHRM4/AKT/MYCN upregulates interferon alpha-17 in the tumor microenvironment to promote neuroendocrine differentiation of prostate cancer. 
  • CRISPR/Cas9-Mediated BRCA1 Knockdown Adipose Stem Cells Promote Breast Cancer Progression. 
  • CaMKK2 in myeloid cells is a key regulator of the immune-suppressive microenvironment in breast cancer. 
  • Calcium/Calmodulin Dependent Protein Kinase Kinase 2 Regulates the Expansion of Tumor-Induced Myeloid-Derived Suppressor Cells. 
  • Can Exercise-Induced Modulation of the Tumor Physiologic Microenvironment Improve Antitumor Immunity? 
  • Cancer-associated fibroblasts promote directional cancer cell migration by aligning fibronectin. 
  • Cancer-cell-derived GABA promotes β-catenin-mediated tumour growth and immunosuppression. 
  • Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. 
  • Cell-programmed nutrient partitioning in the tumour microenvironment. 
  • Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment. 
  • Chemotaxis-driven assembly of endothelial barrier in a tumor-on-a-chip platform. 
  • Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. 
  • Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma. 
  • Classical Hodgkin lymphoma arising in the setting of iatrogenic immunodeficiency: a clinicopathologic study of 10 cases. 
  • Classifying the evolutionary and ecological features of neoplasms. 
  • Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity. 
  • Commentary: Breaking down non-small cell lung cancer tumor microenvironment heterogeneity and predicting response to immune checkpoint inhibitors. 
  • Computational modelling of perivascular-niche dynamics for the optimization of treatment schedules for glioblastoma. 
  • Conditional HIF-1 induction produces multistage neovascularization with stage-specific sensitivity to VEGFR inhibitors and myeloid cell independence. 
  • Controlling cancer-induced inflammation with a nucleic acid scavenger prevents lung metastasis in murine models of breast cancer. 
  • Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma. 
  • Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer. 
  • DC-CIK as a widely applicable cancer immunotherapy. 
  • Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. 
  • Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer. 
  • Designing a broad-spectrum integrative approach for cancer prevention and treatment. 
  • Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma. 
  • Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. 
  • Disruption of crosstalk between mesenchymal stromal and tumor cells in bone marrow as a therapeutic target to prevent metastatic bone disease. 
  • Dissecting the Functional Significance of DNA Polymerase Mutations in Cancer. 
  • Dissecting the immune landscape of tumor draining lymph nodes in melanoma with high-plex spatially resolved protein detection. 
  • Dying glioma cells establish a proangiogenic microenvironment through a caspase 3 dependent mechanism. 
  • Dysfunctional T cell metabolism in the tumor microenvironment. 
  • ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression. 
  • Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype. 
  • Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma. 
  • Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma. 
  • Effects of high-dose microbeam irradiation on tumor microvascular function and angiogenesis. 
  • Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models. 
  • Efficacy and Mechanisms of Aerobic Exercise on Cancer Initiation, Progression, and Metastasis: A Critical Systematic Review of In Vivo Preclinical Data. 
  • Elevation of Stromal-Derived Mediators of Inflammation Promote Prostate Cancer Progression in African-American Men. 
  • Emerging predictive biomarkers in the management of bone and soft tissue sarcomas. 
  • Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity. 
  • Engineering functional 3-dimensional patient-derived endocrine organoids for broad multiplatform applications. 
  • Epigenetics and cancer metabolism. 
  • Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis. 
  • Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes. 
  • Estimation of immune cell content in tumor using single-cell RNA-seq reference data. 
  • Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma. 
  • Evaluation of tumor microenvironment in an animal model using a nanoparticle contrast agent in computed tomography imaging. 
  • Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. 
  • Ex Vivo Tumor-on-a-Chip Platforms to Study Intercellular Interactions within the Tumor Microenvironment. 
  • Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases. 
  • Facts and Hopes for Immunotherapy in Renal Cell Carcinoma. 
  • Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. 
  • Fibulin-3 is a novel TGF-β pathway inhibitor in the breast cancer microenvironment. 
  • Functional CD3+CD8+PD1- T Cell Accumulation and PD-L1 Expression Increases During Tumor Invasion in DCIS of the Breast. 
  • Functional interaction between responses to lactic acidosis and hypoxia regulates genomic transcriptional outputs. 
  • G6PD inhibition sensitizes ovarian cancer cells to oxidative stress in the metastatic omental microenvironment. 
  • GLUT1 Expression in Tumor-Associated Neutrophils Promotes Lung Cancer Growth and Resistance to Radiotherapy. 
  • Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines. 
  • Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. 
  • Glioma progression is shaped by genetic evolution and microenvironment interactions. 
  • Glucose-regulated protein (GRP78) is an important cell surface receptor for viral invasion, cancers, and neurological disorders. 
  • HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase. 
  • HER2-positive breast cancer brain metastasis: A new and exciting landscape. 
  • Hedgehog Signaling Regulates Metabolism and Polarization of Mammary Tumor-Associated Macrophages. 
  • Hedgehog Signaling Regulates Treg to Th17 Conversion Through Metabolic Rewiring in Breast Cancer. 
  • Hepatocellular Carcinoma-The Influence of Immunoanatomy and the Role of Immunotherapy. 
  • Heterogeneity of human prostate carcinoma-associated fibroblasts implicates a role for subpopulations in myeloid cell recruitment. 
  • High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma. 
  • Host factors for risk and survival in lymphoma. 
  • Human Astrocytes Exhibit Tumor Microenvironment-, Age-, and Sex-Related Transcriptomic Signatures. 
  • Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets. 
  • Human mesenchymal stem cell and epithelial hepatic carcinoma cell lines in admixture: concurrent stimulation of cancer-associated fibroblasts and epithelial-to-mesenchymal transition markers. 
  • Humoral immune responses: Unsung heroes of the war on cancer. 
  • IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. 
  • Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy. 
  • Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. 
  • IgA transcytosis and antigen recognition govern ovarian cancer immunity. 
  • Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas. 
  • Immune Microenvironment Landscape in CNS Tumors and Role in Responses to Immunotherapy. 
  • Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. 
  • Immune suppression in gliomas. 
  • Immunologic Effects of Stereotactic Body Radiotherapy in Dogs with Spontaneous Tumors and the Impact of Intratumoral OX40/TLR Agonist Immunotherapy. 
  • Immunometabolism at the crossroads of obesity and cancer-a Keystone Symposia report. 
  • Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. 
  • Immunotherapy for osteosarcoma: Where do we go from here? 
  • Impact of exercise on the immune system and outcomes in hematologic malignancies. 
  • In Vitro Differentiation of Tumor-Associated Macrophages from Monocyte Precursors with Modified Melanoma-Conditioned Medium. 
  • Increased CaMKK2 Expression Is an Adaptive Response That Maintains the Fitness of Tumor-Infiltrating Natural Killer Cells. 
  • Indirect Tumor Cell Death After High-Dose Hypofractionated Irradiation: Implications for Stereotactic Body Radiation Therapy and Stereotactic Radiation Surgery. 
  • Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma. 
  • Injury promotes sarcoma development in a genetically and temporally restricted manner. 
  • Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. 
  • Intratumor heterogeneity in evolutionary models of tumor progression. 
  • Introduction: tumor as an organ. 
  • Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer. 
  • Irradiation and immunotherapy: From concept to the clinic. 
  • JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. 
  • LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma. 
  • Laminin alpha 2 enables glioblastoma stem cell growth. 
  • Learning to distinguish progressive and non-progressive ductal carcinoma in situ. 
  • Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. 
  • Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond. 
  • Lipid droplet velocity is a microenvironmental sensor of aggressive tumors regulated by V-ATPase and PEDF. 
  • Liver Tumor Microenvironment. 
  • LncRNA CamK-A Regulates Ca2+-Signaling-Mediated Tumor Microenvironment Remodeling. 
  • Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. 
  • Loss of Forkhead Box O3 Facilitates Inflammatory Colon Cancer: Transcriptome Profiling of the Immune Landscape and Novel Targets. 
  • Loss of microRNA-21 leads to profound stromal remodeling and short survival in K-Ras-driven mouse models of pancreatic cancer. 
  • MTAP loss correlates with an immunosuppressive profile in GBM and its substrate MTA stimulates alternative macrophage polarization. 
  • Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. 
  • Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. 
  • Management of glioblastoma: State of the art and future directions. 
  • Mast cells impair the development of protective anti-tumor immunity. 
  • Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma. 
  • Matrix compliance permits NF-κB activation to drive therapy resistance in breast cancer. 
  • Metabolic Barriers to T Cell Function in Tumors. 
  • Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma. 
  • Metabolic landscape of the tumor microenvironment at single cell resolution. 
  • Metabolic pattern formation in the tumor microenvironment. 
  • Metabolic plasticity of metastatic breast cancer cells: adaptation to changes in the microenvironment. 
  • Metabolic programming and immune suppression in the tumor microenvironment. 
  • Metabolic reprogramming of the immune response in the tumor microenvironment. 
  • Metabolism and Colorectal Cancer. 
  • Metabolism in the tumor microenvironment: insights from single-cell analysis. 
  • Metaboloptics: Visualization of the tumor functional landscape via metabolic and vascular imaging. 
  • Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors. 
  • MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B. 
  • Microenvironmental influences on T cell immunity in cancer and inflammation. 
  • Microenvironmental regulation of cancer metastasis by miRNAs. 
  • Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine. 
  • Modeling the tumor extracellular matrix: Tissue engineering tools repurposed towards new frontiers in cancer biology. 
  • Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial. 
  • Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma. 
  • Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. 
  • Multiplatform computational analysis of mast cells in adrenocortical carcinoma tumor microenvironment. 
  • Multiregional Radiogenomic Assessment of Prostate Microenvironments with Multiparametric MR Imaging and DNA Whole-Exome Sequencing of Prostate Glands with Adenocarcinoma. 
  • Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression. 
  • Myelopoiesis during Solid Cancers and Strategies for Immunotherapy. 
  • NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms. 
  • Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma. 
  • Neutrophils Create an ImpeNETrable Shield between Tumor and Cytotoxic Immune Cells. 
  • New Approaches to Glioblastoma. 
  • Notch-Induced Myeloid Reprogramming in Spontaneous Pancreatic Ductal Adenocarcinoma by Dual Genetic Targeting. 
  • Novel chemotherapies in development for management of castration-resistant prostate cancer. 
  • Novel enriched pathways in superficial malignant peripheral nerve sheath tumours and spindle/desmoplastic melanomas. 
  • Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. 
  • Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice. 
  • Oncolytic viruses in melanoma. 
  • Optoacoustic imaging identifies ovarian cancer using a microenvironment targeted theranostic wormhole mesoporous silica nanoparticle. 
  • Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. 
  • PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. 
  • PDGF-AA mediates mesenchymal stromal cell chemotaxis to the head and neck squamous cell carcinoma tumor microenvironment. 
  • Pan-PI3Ki targets multiple B-ALL microenvironment interactions that fuel systemic and CNS relapse. 
  • Parallel Expression of Enzyme Inhibitors of CD8T Cell Activity in Tumor Microenvironments and Secretory Endometrium. 
  • Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential? 
  • Personalized and targeted therapy of esophageal squamous cell carcinoma: an update. 
  • Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. 
  • Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer. 
  • Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy. 
  • Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. 
  • Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. 
  • Potentially functional genetic variants in the complement-related immunity gene-set are associated with non-small cell lung cancer survival. 
  • Prognostic value and targeted inhibition of survivin expression in esophageal adenocarcinoma and cancer-adjacent squamous epithelium. 
  • Program death-1 immune checkpoint and tumor microenvironment in malignant liver tumors. 
  • Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies. 
  • RNA-Modified T Cells Mediate Effective Delivery of Immunomodulatory Cytokines to Brain Tumors. 
  • RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics. 
  • Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. 
  • Re-purposing cryoablation: a combinatorial 'therapy' for the destruction of tissue. 
  • Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer. 
  • Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. 
  • Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown. 
  • Revealing the evolution of the tumor immune microenvironment in follicular lymphoma patients progressing within 24 months using single-cell imaging mass cytometry. 
  • Right Time and Place for IL12: Targeted Delivery Stimulates Immune Therapy. 
  • Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion. 
  • Role of dendritic cell metabolic reprogramming in tumor immune evasion. 
  • Role of exosomes in treatment of hepatocellular carcinoma. 
  • STING suppresses bone cancer pain via immune and neuronal modulation. 
  • STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy. 
  • STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. 
  • Safety and Efficacy of Avelumab in Small Bowel Adenocarcinoma. 
  • Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. 
  • Salting the Soil: Targeting the Microenvironment of Brain Metastases. 
  • Shaping the Immune Landscape in Cancer by Galectin-Driven Regulatory Pathways. 
  • Sickle erythrocytes target cytotoxics to hypoxic tumor microvessels and potentiate a tumoricidal response. 
  • Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer. 
  • Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors. 
  • Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease. 
  • Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy. 
  • Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer. 
  • Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer. 
  • Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer. 
  • Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma. 
  • Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling. 
  • Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. 
  • Syngeneic Murine Ovarian Cancer Model Reveals That Ascites Enriches for Ovarian Cancer Stem-Like Cells Expressing Membrane GRP78. 
  • T cell stemness and dysfunction in tumors are triggered by a common mechanism. 
  • T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma. 
  • TGF-β superfamily co-receptors in cancer. 
  • TGF-β-Regulated MicroRNAs and Their Function in Cancer Biology. 
  • TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3. 
  • TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. 
  • Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES). 
  • Targeted Therapy and Immunosuppression in the Tumor Microenvironment. 
  • Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy. 
  • Targeting Hypoxia-Inducible Factor 1α in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment. 
  • Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy. 
  • Targeting Tumor Acidosis and Regulatory T Cells Unmasks Anti-Metastatic Potential of Local Tumor Ablation in Triple-Negative Breast Cancer. 
  • Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer. 
  • Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death. 
  • Temperature matters! And why it should matter to tumor immunologists. 
  • The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures. 
  • The Biology of Pulmonary Metastasis. 
  • The Cancer Epitope Database and Analysis Resource: A Blueprint for the Establishment of a New Bioinformatics Resource for Use by the Cancer Immunology Community. 
  • The Complex Integration of T-cell Metabolism and Immunotherapy. 
  • The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation. 
  • The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment. 
  • The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. 
  • The Lineage-Defining Transcription Factors SOX2 and NKX2-1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment. 
  • The Tumor Macroenvironment: Cancer-Promoting Networks Beyond Tumor Beds. 
  • The Tumor Microenvironment Regulates CD19 and CD20 Immunotherapy for Lymphoma. 
  • The future of biology in driving the field of hyperthermia. 
  • The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial. 
  • The intersection between immunotherapy and laser interstitial thermal therapy: a multipronged future of neuro-oncology. 
  • The role of CAF derived exosomal microRNAs in the tumour microenvironment of melanoma. 
  • The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy. 
  • The value of calprotectin S100A8/A9 complex as a biomarker in colorectal cancer: A systematic review. 
  • Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition. 
  • Three-dimensional culture systems in cancer research: Focus on tumor spheroid model. 
  • Tissue engineered cancer metastases as cancer vaccine to improve cancer immunotherapy. 
  • Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression. 
  • Toward understanding cancer stem cell heterogeneity in the tumor microenvironment. 
  • Toxin-based targeted therapy for malignant brain tumors. 
  • Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. 
  • Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression. 
  • Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma. 
  • Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation. 
  • Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy. 
  • Tumor-induced reshuffling of lipid composition on the endoplasmic reticulum membrane sustains macrophage survival and pro-tumorigenic activity. 
  • Tumor-intrinsic NLRP3-HSP70-TLR4 axis drives premetastatic niche development and hyperprogression during anti-PD-1 immunotherapy. 
  • Tumor-intrinsic and immune modulatory roles of receptor-interacting protein kinases. 
  • Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. 
  • UBE2N Promotes Melanoma Growth via MEK/FRA1/SOX10 Signaling. 
  • Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective. 
  • Understanding the tumor microenvironment and radioresistance by combining functional imaging with global gene expression. 
  • Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. 
  • Using genetically encoded fluorescent biosensors to interrogate ovarian cancer metabolism. 
  • Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer. 
  • Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling. 
  • c-Maf: a bad influence in the education of macrophages. 
  • cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma. 
  • miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. 
  • miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy. 
• 

  Keywords of People

  • Badea, Cristian Tudorel, Professor in Radiology, Biomedical Engineering
  • Blobe, Gerard Conrad, Professor of Medicine, Duke Science & Society
  • Goodwin, Courtney Rory, Assistant Professor of Neurosurgery, Radiation Oncology
  • Hanks, Brent A., Associate Professor of Medicine, Pharmacology & Cancer Biology
  • Johnson, G. Allan, Charles E. Putman University Distinguished Professor of Radiology, Biomedical Engineering
  • López, Giselle Yvette, Assistant Professor in Pathology, Pathology
  • MacLeod, Amanda S, Adjunct Associate Professor in the Department of Dermatology, Integrative Immunobiology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Palmer, Gregory M., Associate Professor of Radiation Oncology, Radiation Oncology
  • Pirozzi, Christopher, Assistant Professor in Pathology, Pathology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Zennadi, Rahima, Associate Professor in Medicine, Pathology